VISIT US IN CHICAGO JUNE 2-4 AT BOOTH 2073!

Dr. Chowdhury on Separate Roles of Pazopanib and Pembrolizumab in RCC

Simon Chowdhury, MA, MBBS, MRCP, PhD
Published: Wednesday, Jul 12, 2017



Simon Chowdhury, MA, MBBS, MRCP, PhD, consultant medical oncologist specializing in urological cancer, Sarah Cannon Research Institute, United Kingdom, discusses what roles pazopanib (Votrient) and pembrolizumab (Keytruda) have as monotherapy for patients with renal cell carcinoma (RCC).

Pazopanib is a standard first-line treatment and will remain as such, until additional data are reported out. However, Chowdhury adds that pazopanib could be combined with other immunotherapies aside from pembrolizumab that work differently.

Regarding pembrolizumab, there are promising combination data with axitinib (Inlyta)—a regimen now being explored in a phase III study in the frontline setting. 


Simon Chowdhury, MA, MBBS, MRCP, PhD, consultant medical oncologist specializing in urological cancer, Sarah Cannon Research Institute, United Kingdom, discusses what roles pazopanib (Votrient) and pembrolizumab (Keytruda) have as monotherapy for patients with renal cell carcinoma (RCC).

Pazopanib is a standard first-line treatment and will remain as such, until additional data are reported out. However, Chowdhury adds that pazopanib could be combined with other immunotherapies aside from pembrolizumab that work differently.

Regarding pembrolizumab, there are promising combination data with axitinib (Inlyta)—a regimen now being explored in a phase III study in the frontline setting. 



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
34th Annual Miami Breast Cancer Conference® Clinical Case Vignette Series™May 25, 20182.0
Community Practice Connections™: CDK4/6 Inhibitors With the Experts: The Role of Emerging Agents for the Management of Metastatic Breast CancerMay 30, 20182.0
Publication Bottom Border
Border Publication
x